Please try another search
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.
Name | Age | Since | Title |
---|---|---|---|
William Jones | 59 | 2023 | Independent Director |
Nimish P. Shah | 45 | 2023 | Independent Director |
Michael Thomas Henderson | 34 | 2022 | CEO & Director |
Peter Evan Harwin | 38 | 2022 | Independent Director |
Andrew Gottesdiener | 32 | 2023 | Independent Director |
Tomas Kiselak | 37 | 2023 | Independent Director |
Mark C. McKenna | 48 | 2023 | Independent Chairman of the Board |
Lisa Bollinger | - | 2024 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review